Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Testing Firm NeoGenomics Eyes $7.8M from Public Offering of Stock

NEW YORK (GenomeWeb News) – NeoGenomics today announced the public offering of 3.15 million shares of its common stock at $3.00 per share.

The Ft. Myers, Fla.-based firm which specializes in cancer genetic testing, is selling 2.85 million shares, while a shareholder, the Mary S. Dent Gifting Trust, will sell 300,000 shares.

NeoGenomics expects to raise $7.8 million in net proceeds from the offering. It will not receive any proceeds from Mary S. Dent's sale of its shares.

The company will use the raise to pay down certain indebtedness and general corporate and operating purposes, it said. Craig-Hallum Capital is the book-running manager on the offering. Ladenburg Thalmann & Co., and Emerging Growth Equities are co-managers.

NeoGenomics has granted the underwriters a 30-day option to purchase up to an additional 472,500 shares cover any over-allotments.

The firm recently moved to the Nasdaq from the OTC Bulletin Board.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.